Why is the Supreme Court investigating medical pricing?
The Supreme Court of India has initiated a rigorous inquiry into the government and private hospital industry regarding the extreme disparity between the procurement costs and the final retail prices of oncology drugs. The judicial intervention follows evidence presented before the bench detailing instances where medications, such as a cancer injection costing Rs 11,000 to procure, were billed to patients at Rs 1.3 lakh. The court has characterized these exorbitant margins as a form of "dacoity" or "loot," questioning why the regulatory framework has largely failed to prevent such financial burdens on the public.
How do drug prices currently function in India?
In India, pharmaceutical pricing is governed by the Drug Price Control Order (DPCO), which regulates a specific subset of essential medicines. However, approximately 90% of drugs remain outside the direct purview of this regulatory ceiling, allowing manufacturers and hospitals to set their own Maximum Retail Price (MRP). While the central government has defended the principles of free-market drug pricing, the Supreme Court has challenged this stance, specifically inquiring why the regulatory system appears structured to prioritize the interests of pharmaceutical manufacturers and large hospital chains over the affordability of essential medical treatments.
"Why is the entire system working to help pharmaceutical manufacturers?" the Supreme Court bench asked, expressing deep frustration over the massive gap between the cost of medicines and the final bills presented to patients.
What is the proposed solution to curb medical costs?
The Supreme Court has suggested the implementation of a uniform 16% cap on profit margins for medicines as a potential remedy to protect patients from predatory pricing. While the judiciary has yet to issue a final ruling, it has reserved its verdict following a Public Interest Litigation (PIL) that highlighted the lack of oversight. During the proceedings, the bench specifically scrutinized major healthcare providers, including mentions of Fortis Healthcare in the context of broader pricing concerns. The court's primary objective is to force a reconciliation between hospital revenue models and the fundamental right to affordable healthcare, explicitly asking the Centre to justify the long-standing delay in regulating margins for critical cancer treatments.
What are the implications for the Indian healthcare sector?
The ongoing legal battle highlights a systemic tension between the profitability of private healthcare providers and the government’s obligation to ensure essential medicine remains accessible. For international observers, this case is significant as it reflects a growing domestic movement in India to expand price controls beyond the existing DPCO list. As the case progresses, the government faces increasing pressure to explain why such high markups have been allowed to persist unchecked for years, potentially signaling a shift toward more stringent oversight of the pharmaceutical supply chain and hospital billing practices nationwide.
